We are live on ! Find out more
AIM

AIM ImmunoTech
AIM

30 hedge funds and large institutions have $3.01M invested in AIM ImmunoTech in 2023 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

47% more capital invested

Capital invested by funds: $2.05M → $3.01M (+$959K)

3% less funds holding

Funds holding: 31 → 30 (-1)

17% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 6

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

Holders
30
Holders Change
-1
Holders Change %
-3.23%
% of All Funds
0.47%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
3
Reduced
4
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$21.6K
2
DS
DRW Securities
Illinois
+$17.9K
3
Jane Street
Jane Street
New York
+$10.7K
4
DBRC
D.B. Root & Company
Pennsylvania
+$5.84K
5
Renaissance Technologies
Renaissance Technologies
New York
+$4.87K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$84.5K
2
BlackRock
BlackRock
New York
-$52.9K
3
Rockefeller Capital Management
Rockefeller Capital Management
New York
-$17K
4
Citadel Advisors
Citadel Advisors
Florida
-$12.9K
5
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors
Iowa
-$9K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$1.33M – – –
BlackRock
2
BlackRock
New York
$474K -$52.9K -1,096 -13%
Morgan Stanley
3
Morgan Stanley
New York
$292K -$84.5K -1,752 -29%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$255K – – –
Renaissance Technologies
5
Renaissance Technologies
New York
$120K +$4.87K +101 +6%
State Street
6
State Street
Massachusetts
$116K – – –
Verition Fund Management
7
Verition Fund Management
Connecticut
$93.8K -$1.93K -40 -3%
BCM
8
Bridgeway Capital Management
Texas
$73K – – –
Northern Trust
9
Northern Trust
Illinois
$58K – – –
Susquehanna International Group
10
Susquehanna International Group
Pennsylvania
$36.6K +$21.6K +447 +447%
DS
11
DRW Securities
Illinois
$25K +$17.9K +370 New
SWM
12
SeaCrest Wealth Management
New York
$24.8K – – –
Bank of New York Mellon
13
Bank of New York Mellon
New York
$16.9K – – –
Jane Street
14
Jane Street
New York
$14.8K +$10.7K +222 New
CAPTRUST Financial Advisors
15
CAPTRUST Financial Advisors
North Carolina
$13.4K – – –
FWM
16
ForthRight Wealth Management
Georgia
$13.4K – – –
CB
17
Community Bank
New York
$8.86K – – –
DBRC
18
D.B. Root & Company
Pennsylvania
$8.07K +$5.84K +121 New
TCM
19
Traynor Capital Management
Pennsylvania
$7.89K – – –
TSS
20
Two Sigma Securities
New York
$6.9K -$3.04K -63 -38%
SFG
21
SNS Financial Group
Minnesota
$6.7K – – –
Bank of America
22
Bank of America
North Carolina
$3.35K +$2.41K +50 New
TRCT
23
Tower Research Capital (TRC)
New York
$3.21K +$1.4K +29 +153%
Osaic Holdings
24
Osaic Holdings
Arizona
$1.52K – – –
HI
25
Hoey Investments
Pennsylvania
$670 – – –
1
2

AIM Hedge Fund Activity: Q2 2023 in Review

30 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q2 2023, worth a combined $3.01M — up 47% from $2.05M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of AIM and 5 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 3 added.

The largest buyer was Susquehanna International Group, adding an estimated $21.6K. The largest seller was Morgan Stanley, cutting an estimated $84.5K.

  • 30 institutional investors held AIM ImmunoTech (AIM) as of Q2 2023, down from 31 in Q1 2023.
  • Funds reported $3.01M of AIM ImmunoTech stock for Q2 2023, up 47% quarter-over-quarter.
  • 5 funds opened new AIM ImmunoTech positions in Q2 2023 and 6 closed out, a net change of -1 holder.
  • The largest AIM ImmunoTech buyer in Q2 2023 was Susquehanna International Group, an estimated $21.6K added.
  • The largest AIM ImmunoTech seller in Q2 2023 was Morgan Stanley, an estimated $84.5K sold.

Based on aggregated 13F filings for Q2 2023.